Executive Interview: Gitte Aabo On Leo Pharma's Innovation Strategy
The head of Denmark's multinational specialty dermatology company has unveiled a strategy to the year 2025 that includes a large increase in R&D spending, a continued interest in bulking up its established products business, and improving its commercial presence in Latin America and other markets.
You may also be interested in...
Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.